christophe rochais

Professor

Université de Caen Normandie

France

Research Interests

Explore related searches

Professors in France

Contact this professor

ORCID

Google Scholar

About

Christophe Rochais is a Professor at Université de Caen Normandie, France. His research focuses on medicinal chemistry with an emphasis on Alzheimer's disease and breast cancer, investigating novel drug derivatives, their synthesis, and biological evaluation. Recent articles highlight his work on drug repurposing, innovative targeting strategies, and the development of multi-target ligands.

christophe rochais

Research Interests

Explore related searches

Contact this professor

About

Articles (25)

Shaping Future Medicinal Chemists: Perspectives from European Schools of Pharmacy within the GP2A Network

A combined experimental and computational insights into novel sulfa drug derivatives: Synthesis, DNA binding, molecular docking and DFT studies

Targeting together cholinesterases and serotonin reuptake against Alzheimer’s disease

Implication of Central β2 Adrenergic Receptor for the Development of Novel Drugs Against Alzheimer's Disease

Analysis of skeletal diversity of multi-target directed ligands (MTDLs) targeting Alzheimer's disease

Anti-Breast Cancer Properties and In Vivo Safety Profile of a Bis-Carbazole Derivative

Evidence from a mouse model supports repurposing an anti-asthmatic drug, bambuterol, against Alzheimer’s disease by administration through an intranasal route

Inducing neuronal regeneration and differentiation via the BDNF/TrkB signaling pathway: a key target against neurodegenerative diseases?

Indirect influence on the BDNF/TrkB receptor signaling pathway via GPCRs, an emerging strategy in the treatment of neurodegenerative disorders

Discovery of a pocket network on the domain 5 of the TrkB receptor – A potential new target in the quest for the new ligands

Studies on the mechanisms of action of MR33317

Synthesis and interest in medicinal chemistry of β-phenylalanine derivatives (β-PAD): an update (2010–2022)

Dynamic microfluidic single-cell screening identifies pheno-tuning compounds to potentiate tuberculosis therapy

Development of Pleiotropic TrkB and 5-HT4 Receptor Ligands as Neuroprotective Agents

Synthesis, in Vitro and in Vivo Biological Evaluation of Novel Dual Compounds Targeting Both Acetylcholinesterase and Serotonergic 5-HT4 Receptors with Potential Interest in the Treatment of Alzheimer’s Disease.

Design, synthesis and biological characterization of novel activators of the TrkB neurotrophin receptor

C3-Symmetric Ligands in Drug Design: When the Target Controls the Aesthetics of the Drug

Conceptual Framework of the Design of Pleiotropic Drugs against Alzheimer’s Disease

Biginelli Reaction Synthesis of Novel Multitarget-Directed Ligands with Ca<sup>2+</sup> Channel Blocking Ability, Cholinesterase Inhibition, Antioxidant Capacity, and Nrf2 Activation

Advances in prodrug design for Alzheimer’s disease: the state of the art

29th Annual GP2A Medicinal Chemistry Conference

5-HT4R modulators: a patent landscape

Disproportionality analysis in VigiBase as a drug repositioning method for the discovery of potentially useful drugs in Alzheimer's disease

Aminothiaindanone as an accessible scaffold for a three-point chemical diversity.

Development of Novel Potential Pleiotropic Compounds of Interest in Alzheimer’s Disease Treatment through Rigidification Strategy

Collaborators (24)

Laura Carro

Patrick Dallemagne

Frederic BONHOMME

Florence McCarthy

Jana Sopkova-de Oliveira Santos

hélène MARTIN

ronan bureau

Lhassane Ismaili

Serge Mignani

Marc Since

Vânia Moreira

Krzysztof Jozwiak

Ioannis Charalampopoulos

Annaluisa Mariconda

Artur Wnorowski

Audrey DAVIS

Niamh M. O'Boyle

Susan E Matthews

Aurélie Malzert-Freon

Alban Lepailleur

Francesca Giuntini

Samuel BERTRAND

Jean-Yves Tinevez

Pascal Marchand

How do I reach out?

Meet Kite AI